1,312
Views
19
CrossRef citations to date
0
Altmetric
Research Article

Antiplatelet Activity of α.- and β.-Amyrin, Isomeric Mixture from Protium heptaphyllum.

, , , , &
Pages 343-349 | Accepted 01 Dec 2006, Published online: 07 Oct 2008
 

Abstract

A mixture of triterpenes named α.- and β.-amyrin (AMI), isolated from the Brazilian medicinal herb Protium hetaphyllum. (Aubl) March (Burseraceae), was evaluated for the ability to inhibit aggregation of human platelets induced by adenosine 5′-diphosphate (ADP, 1.5 and 3 µM), collagen, and arachidonic acid (AA) in vitro.. The results showed that AMI significantly inhibited platelet aggregation (40, 64, and 60%) in the assay carried out with ADP (3 µM) as agonist, at the doses of 100, 150, and 200 µM, respectively. In the presence of a lower ADP concentration (1.5 µM), a 3-time higher percentage of inhibition (32%) was observed with AMI 50 µM, as compared to that seen with 3.0 µM ADP. In the test using collagen (10 µg/mL) as agonist, AMI (50, 100, and 150 µM) inhibited aggregation by 26, 47, and 39%, respectively, while in the presence of the arachidonic acid (150 µM) at the doses of 50, 100, 150, and 200 µM, it inhibited platelet aggregation by 20, 21, 25, and 27%, respectively. The lowest IC50 value for the AMI inhibitory effect was observed with collagen (90.0 µM), followed by ADP (117.9 µM) and arachidonic acid (181.4 µM). With ADP as agonist, the anti-aggregant effect of the acetylsalicylic acid (ASA) was potentiated by AMI but not by dipyridamole. No potentiation was observed after the combination of ASA and AMI with collagen or arachidonic acid as agonists. Our results indicated that AMI possesses a platelet anti-aggregant activity in a concentration-dependent manner and probably acts on a biochemical pathway common to all the agonists tested.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.